This week’s biotechnology news headlines include, Ebola shows efficacy in small clinical trial, FDA approves UCB’s seizure drug, seven pharma companies join to fight Parkinson’s, Teva offers concessions over Allergan deal, industry wants more leniency in FDA draft guidance, Amgen and UCB osteoporosis drug meets goal in clinical trial, and ViiV completes acquisition of BMS’ HIV assets.
Cell Culture Events
Ask the Expert:
Bioprinting is now a word most people have heard of, but might not really understand. Because there is a lot of hype regarding what is possible and what has already been accomplished, the term likely conjures up images of Frankenstein, a mouse with an ear growing on its back, glow-in-the-dark animals, or cyborgs.
The industry has come a long way from the time when researchers hacked into a desktop printer to experiment with printing out living cells. Researchers are now able to create vascularized tissue constructs that have proven viable when implanted into animals. But while printing of whole organs remains elusive (and probably won’t happen for many years), there are many applications for bioprinting that are commercially feasible and applicable today.
Pharmaceutical companies are faced with expensive, time-consuming, failure-prone clinical trials in order to get their drugs approved and on the market. A whole textbook could be written on why they are so expensive and risky, and companies must innovate their drug discovery and development processes. Izumi International, Inc. has been working with some of the top names in the pharmaceutical industry to optimize their drug discovery and production processes and incorporate bioprinting into their workflows. This will ultimately contribute to a much more streamlined and productive development framework, as the data generated from 3D assays vastly outperforms that from traditional 2D workflows.
This Ask the Expert session is hosted by Katie Golson of Izumi International, Inc. Katie joined Izumi in 2014 as a Biomedical Automation Application Engineer where she helps develop customized laboratory automation and bioprinting solutions for companies and universities all over the world. She holds a Master’s in Bioengineering from University of California, San Diego and a Bachelor’s in Industrial Design from Georgia Institute of Technology. Her prior experience running automated liquid handling at Vertex Pharmaceuticals
Ask your questions about bioprinting starting Monday!
Progress in Continuous Biomanufacturing – June 27-28, 2016 – Robinson College, Cambridge, UK
The conference is enhanced by the participation of several leading industrial technologists, scientific, vendors and also leading academics from Europe and USA. They have come forward to share their experience and knowledge to provide a better understanding of the current technologies and their application in continuous biomanufacturing. There is also a plenary lecture by a distinguished professor in the field of bioprocessing, and you will also benefit from access to unpublished data. This meeting will address several advancements and their successful application with data in the Technology both Upstream and downstream and also on Initiatives to process developments and project to the future direction of the industry. By joining with us you can benefit from the current state of-the-art advancements in continuous manufacturing and also learn about the successful organisations that are developing and applying these methods in-house.
Check out the Top Blogs, Top Ask the Expert Sessions and Top Cool Tool Features of 2015 –
“AstraZeneca, Pfizer and Eli Lilly are among seven major pharmaceutical companies linking into a “ground-breaking” consortium striving to streamline and accelerate the development of new therapies for Parkinson’s disease.”
If you like this story, please see our blog titled “3D Bioprinting and 4D Bioprinting – Applications and Technologies”
“Teva Pharmaceutical Industries Ltd (TEVA.TA) has offered concessions to allay EU antitrust concerns over its $40.5 billion bid for Allergan’s (AGN.N) generics unit which will cement its position as the world’s largest generics drugmaker.”
If you like this story, please see our blog titled “2015 FDA New Drug Approvals – 13 Biologics Receive Approval”